Two Step Haplo With Radiation Conditioning
Plain-language summary
This trial is testing a two-step haploidentical (half-matched) stem cell transplant using radiation-based reduced-intensity conditioning for patients with adult T-cell leukemia/lymphoma (ATLL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Fludarabine (DRUG): Given IV | Total-Body Irradiation (RADIATION): Undergo TBI | Donor Lymphocyte Infusion (PROCEDURE): Undergo DLI | Cyclophosphamide (DRUG): Given IV | Tacrolimus (DRUG): Given IV | Mycophenolate Mofetil (DRUG): Given IV | Hematopoietic Cell Transplantation (PROCEDURE): Undergo HSCT | Melphalan (DRUG): Given IV | Bone Marrow Aspiration and Biopsy (PROCEDURE): Undergo bone marrow aspiration/ biopsy | Diagnostic Imaging (PROCEDURE): Undergo diagnostic imaging | Biospecimen Collection (PROCEDURE): Undergo blood sample collection
Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, Biospecimen Collection
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details